Tetrahedral DNA nanostructure based siRNA delivery vehicle for braf gene silencing and MEK-ERK pathway inhibition in the treatment of refractory thyroid cancer

1. Global burden of thyroid cancer from 1990 to 201710.1001/jamanetworkopen.2020.8759 ↗

2. The 5th edition of WHO classification of tumors of endocrine organs: changes in the diagnosis of follicular-derived thyroid carcinoma10.1007/s12020-023-03336-4 ↗

3. V600EBRAF inhibition induces cytoprotective autophagy through AMPK in thyroid cancer cells10.3390/ijms22116033 ↗

4. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks10.1038/s41467-024-47581-1 ↗

5. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients10.18632/oncotarget.7811 ↗

6. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma10.1089/thy.2020.0322 ↗

7. PD-1 Blockade in anaplastic thyroid carcinoma10.1200/JCO.19.02727 ↗

8. MAPK pathway inhibitors in thyroid cancer: preclinical and clinical data10.3390/cancers15030710 ↗

9. Thyroid cancer: a review10.1001/jama.2023.26348 ↗

10. Clinical development of BRAF plus MEK inhibitor combinations10.1016/j.trecan.2020.05.009 ↗

11. Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia10.1056/NEJMoa2031298 ↗

12. Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers10.1172/JCI120966 ↗

13. Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer10.1186/s12943-022-01696-5 ↗

14. Therapeutic siRNA: state of the art10.1038/s41392-020-0207-x ↗

15. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application10.1038/nrd3010 ↗

16. Delivery materials for siRNA therapeutics10.1038/nmat3765 ↗

17. Noncoding RNA therapeutics - challenges and potential solutions10.1038/s41573-021-00219-z ↗

18. Lipid nanoparticle technology for clinical translation of siRNA therapeutics10.1021/acs.accounts.9b00368 ↗

19. Targeted-gene silencing of BRAF to interrupt BRAF/MEK/ERK pathway synergized photothermal therapeutics for melanoma using a novel FA-GNR-siBRAF nanosystem10.1016/j.nano.2018.04.010 ↗

20. Liposomal siRNA delivery in papillary thyroid carcinoma cells10.1007/978-1-0716-2505-7_9 ↗

21. Automated screening of primary cell-based aptamers for targeting and therapy of pancreatic cancer

22. A novel therapeutic vaccine based on graphene oxide nanocomposite for tumor immunotherapy10.1016/j.cclet.2022.01.071 ↗

23. A bioswitchable delivery system for microRNA therapeutics based on a tetrahedral DNA nanostructure

24. Framework nucleic acid-based and neutrophil-based nanoplatform loading baicalin with targeted drug delivery for anti-inflammation treatment10.1021/acsnano.4c12917 ↗

25. Development of an inhalable DNA tetrahedron MicroRNA sponge

26. Framework nucleic acid-based selective cell catcher for endogenous stem cell recruitment

27. Targeting modulation of intestinal flora through oral route by an antimicrobial nucleic acid-loaded exosome-like nanovesicles to improve Parkinson’s disease10.1016/j.scib.2024.10.027 ↗

28. Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer10.1148/radiol.2020201791 ↗

29. Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: a comprehensive review10.1111/cas.14934 ↗

30. From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), C.I.R.A.(. Cardiovascular and Interventional Radiology Society of Europe (CIRSE), E.S.o.M.I.N.T.(. Congress of Neurological Surgeons (CNS), E.S.O.(. European Society of Neuroradiology (ESNR), S.o.I.R.(. Society for Cardiovascular Angiography and Interventions (SCAI), a.W.S.O.(. Society of NeuroInterventional Surgery (SNIS), D. Sacks, B. Baxter, B. Campbell, J.S. Carpenter, C. Cognard, D. Dippel, M. Eesa, U. Fischer, K. Hausegger, J.A. Hirsch, M. Shazam Hussain, O. Jansen, M.V. Jayaraman, A.A. Khalessi, B.W. Kluck, S. Lavine, P.M. Meyers, S. Ramee, D.A. Rüfenacht, C.M. Schirmer, D. Vorwerk, Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke, Int J Stroke. 13 (2018) 612-632, https://doi.org/10.1177/1747493018778713.

31. Engineered matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids10.1038/s41563-024-01908-x ↗

32. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study

33. Establishment and maintenance of thyroid organoids from human cancer cells

34. Membrane-wrapped nanoparticles for nucleic acid delivery10.1039/D2BM00447J ↗

35. Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies10.1158/1078-0432.CCR-18-2953 ↗

36. JC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry10.1038/cddis.2012.171 ↗

37. RNA-binding protein ZCCHC4 promotes human cancer chemoresistance by disrupting DNA-damage-induced apoptosis10.1038/s41392-022-01033-8 ↗

38. The role of cystine/glutamate antiporter SLC7A11/xCT in the pathophysiology of cancer10.3389/fonc.2022.858462 ↗

39. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery10.1038/nnano.2012.73 ↗

40. A DNA tetrahedron-based nanosuit for efficient delivery of amifostine and multi-organ radioprotection

41. Synergistic osteogenic and antiapoptotic framework nucleic acid complexes prevent diabetic osteoporosis

42. Framework nucleic acids-based VEGF signaling activating system for angiogenesis: a dual stimulation strategy

43. DNA framework signal amplification platform-based high-throughput systemic immune monitoring10.1038/s41392-024-01736-0 ↗

44. A DNA tetrahedron-based ferroptosis-suppressing nanoparticle: superior delivery of curcumin and alleviation of diabetic osteoporosis10.1038/s41413-024-00319-7 ↗

45. Functionalized DNA nanomaterials targeting toll-like receptor 4 prevent bisphosphonate-related osteonecrosis of the jaw via regulating mitochondrial homeostasis in macrophages10.1002/adfm.202213401 ↗

46. Tetrahedral framework nucleic acids based small interfering RNA targeting receptor for advanced glycation end products for diabetic complications treatment10.1021/acsnano.3c06999 ↗

47. Liver-targeted delivery of small interfering RNA of C-C chemokine receptor 2 with tetrahedral framework nucleic acid attenuates liver cirrhosis10.1021/acsami.2c22579 ↗

48. DNA nanostructure-programmed like-charge attraction at the cell-membrane interface10.1021/acscentsci.8b00383 ↗

49. Geometry of a DNA nanostructure influences its endocytosis: cellular study on 2D, 3D, and in vivo systems10.1021/acsnano.2c01382 ↗

50. Programmable tetrahedral DNA-RNA nanocages woven with stimuli-responsive siRNA for enhancing therapeutic efficacy of multidrug-resistant tumors

51. Enhancing neuronal cell uptake of therapeutic nucleic acids with tetrahedral DNA nanostructures10.1002/smll.202309140 ↗

52. A self-assembled DNA tetrahedron as a carrier for in vivo liver-specific delivery of siRNA10.1039/C9BM01769K ↗

53. BRAFV600E transduction of an SV40-immortalized normal human thyroid cell line induces dedifferentiated thyroid carcinogenesis in a mouse Xenograft model10.1089/thy.2019.0301 ↗

54. PFKFB3 facilitates cell proliferation and migration in anaplastic thyroid carcinoma via the WNT/β-catenin signaling pathway10.1007/s12020-024-03725-3 ↗

55. Defining the in vivo role of mTORC1 in thyrocytes by studying the TSC2 conditional knockout mouse model10.1089/thy.2024.0053 ↗

56. Patient discomfort in relation to thyroid nodule fine-needle aspiration (FNA) performed with or without parenteral and/or topical anesthetic10.4158/EP-2020-0403 ↗

57. Herbal melanin inhibits colorectal cancer cell proliferation by altering redox balance, inducing apoptosis, and modulating MAPK signaling

58. A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis10.1016/S1534-5807(01)00116-2 ↗

59. Mitochondrial membrane permeabilization in cell death10.1152/physrev.00013.2006 ↗

60. Polypyridyl Ruthenium(II) complex-induced mitochondrial membrane potential dissipation activates DNA damage-mediated apoptosis to inhibit liver cancer10.1016/j.ejmech.2018.12.041 ↗

61. Isoform- and phosphorylation-specific multiplexed quantitative pharmacodynamics of drugs targeting PI3K and MAPK signaling in xenograft models and clinical biopsies10.1158/1535-7163.MCT-20-0566 ↗

62. V600E)BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism10.1016/j.canlet.2013.02.033 ↗

63. Echinacoside induces mitochondria-mediated pyroptosis through Raf/MEK/ERK signaling in non-small cell lung cancer cells10.1155/2022/3351268 ↗

64. MGluR5 activity is required for the induction of ethanol behavioral sensitization and associated changes in ERK MAP kinase phosphorylation in the nucleus accumbens shell and lateral habenula10.1016/j.bbr.2019.03.038 ↗

65. Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites10.1016/j.ccell.2023.11.007 ↗

66. Patient-derived model systems and the development of next-generation anticancer therapeutics10.1016/j.cbpa.2020.01.002 ↗

67. Organoid cultures derived from patients with papillary thyroid cancer10.1210/clinem/dgab020 ↗

68. Exosome-like vesicles derived from Hertwig's epithelial root sheath cells promote the regeneration of dentin-pulp tissue10.7150/thno.43156 ↗